Hematologic Oncology

December 5, 2020 - Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.

December 5, 2020 - KO-539, an oral, selective menin-inhibitor, demonstrated activity in patients with relapsed/refractory acute myeloid leukemia in preliminary findings from the ongoing first-in-human KOMET-001 trial.

December 5, 2020 - Ruxolitinib was found to elicit a significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement versus best available therapy in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

December 4, 2020 - The first patient with higher-risk myelodysplastic syndrome has been dosed with a novel combination comprised of the next-generation CD47 blocker ALX148 plus azacitidine as part of the phase 1/2 ASPEN-02 study, the first of several planned studies to examine the agent in those with myeloid malignancies.

The ability to increase the efficacy and decrease the toxicity of treatment regimens in classical Hodgkin lymphoma had stood at odds until the introduction of response-adapted treatment approaches, antibody-drug conjugates, and checkpoint inhibitors to the paradigm.

Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.

Nirav N. Shah, MD, associate professor​, Medical College of Wisconsin, discusses ​the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Novel agents that disrupt protein-protein interactions in the MLL network may be the key to unlocking new therapeutic avenues for patients with acute leukemias.

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.

Emily C. Ayers, MD, hematologist​/oncologist​, assistant professor, University of Virginia Health, discusses the evolving treatment landscape in chronic lymphocytic leukemia.

Joseph G. Jurcic, MD, discusses strategies to optimize patient selection for luspatercept in MDS.

The combination of 10-day decitabine with venetoclax elicited responses and was found to be well tolerated in older patients with newly diagnosed acute myeloid leukemia who are ineligible for chemotherapy.

The use of response-based consolidation coupled with radiation therapy was found to be effective and well tolerated, with low failure rates, in pediatric patients with high-risk classical Hodgkin lymphoma.

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

November 30, 2020 - The FDA has granted a fast track designation to eprenetapopt as a treatment for patients with TP53-mutant acute myeloid leukemia.

The FDA has granted a priority review designation to a new drug application for belumosudil for the treatment of patients with chronic graft-versus-host disease.

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

Kathleen ​A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

November 23, 2020 - The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include the combination of decitabine and cedazuridine as a category 2a recommendation for the treatment of adult patients with intermediate- and high-risk MDS.

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

November 18, 2020 - The FDA has granted a fast track designation to the BTK inhibitor rilzabrutinib for the treatment of patients with immune thrombocytopenia.